Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Analysis of patient-reported outcomes from the IMbrave150 trial found clinically meaningful benefits in terms of quality of life, functioning, and disease symptoms with atezolizumab plus bevacizumab compared with sorafenib in patients with unresectable hepatocellular carcinoma.

The Lancet Oncology